Valuation: Quest PharmaTech Inc.

Market Cap 42.28L 29.74L 26.04L 23.99L 22.27L 28Cr 42.85L 2.87Cr 1.12Cr 14Cr 1.12Cr 1.09Cr 48Cr P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 52.14L 36.67L 32.11L 29.58L 27.46L 35Cr 52.84L 3.54Cr 1.38Cr 17Cr 1.38Cr 1.35Cr 60Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 month-16.67%
3 months-16.67%
6 months-37.50%
Current year-28.57%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.04
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap.
12/12OtherCompany 0 0%
21/25/21Other

Chief Executive Officer

10,00,000 0.5913%
21/25/21Other

Chief Executive Officer

7,00,000 0.4139%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-28.57%-66.67% 29.77L
+1.08%+7.56%+3.61%+9.84% 4.99TCr
+0.40%-1.37%+401.69%+625.15% 4.02TCr
-0.52%+6.57%+25.41%-5.37% 3.46TCr
+3.97%+6.71%+26.06%+63.36% 3.31TCr
-4.19%-1.84%+3.76%+32.17% 2.75TCr
-2.40%+1.60% - - 1.7TCr
+1.34%+5.68%+75.77%+141.51% 1.59TCr
-0.95%+0.76%+12.92%+21.59% 1.39TCr
+1.69%+3.09%+93.44%+99.19% 1.35TCr
Average +0.04%+6.32%+68.23%+102.31% 2.46TCr
Weighted average by Cap. +0.24%+4.49%+91.13%+141.42%

Financials

2025 2026
Net sales - -
Net income -18.01L -12.67L -11.09L -10.22L -9L -12Cr -18.25L -1.22Cr -47.6L -5.93Cr -47.57L -46.53L -21Cr 49.98L 35.15L 30.79L 28.36L 26.32L 34Cr 50.66L 3.39Cr 1.32Cr 16Cr 1.32Cr 1.29Cr 57Cr
Net Debt 8L 6L 5L 5L 4L 5.33Cr 8L 53.98L 21.01L 2.62Cr 21L 20.53L 9.08Cr 10L 7L 6L 6L 5L 6.61Cr 10L 66.94L 26.05L 3.25Cr 26.03L 25.46L 11Cr
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
06/26/06 CA$0.0250 0.00% 1,92,998
03/26/03 CA$0.0250 0.00% 15,000
02/26/02 CA$0.0250 0.00% 5,000
30/26/30 CA$0.0250 0.00% 42,901